Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.71 |
| ▸ | USP2 | O75604 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 5/20 | 0.51 |
| ▸ | PKM | P14618 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585153 | 1.00 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL1249808 | 1.00 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL5321753 | 0.87 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL1248325 | 0.87 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL20912657 | 0.87 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL20912658 | 0.87 | SLC7A5 (0.71) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL9316604 | 0.87 | SLC7A5 (0.60) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL20299944 | 0.86 | SLC7A5 (0.69) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL20299963 | 0.86 | SLC7A5 (0.69) | SLC7A5USP2KDM4EALOX15PTGS1 | |
| SCHEMBL3981521 | 0.86 | SLC7A5 (0.69) | SLC7A5USP2KDM4EALOX15PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| CN-116615205-A | Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116615227-A | Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| WO-2022204806-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-10-06 | — | — | WO | claimed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | claimed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | claimed |
| WO-2022077121-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| EP-3956348-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | Feldan Bio Inc. (CA) | 2022-02-23 | — | — | EP | claimed |
| CN-114008210-A | Peptide-based non-protein cargo delivery | 费尔丹生物公司 | 2022-02-01 | — | — | CN | claimed |
| WO-2020210916-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2020-10-22 | — | — | WO | claimed |
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | disclosed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | disclosed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | disclosed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | disclosed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | disclosed |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4201951-B1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | disclosed |
| CN-116615205-A | Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression | 费尔丹生物公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116615227-A | Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof | 费尔丹生物公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023117904-A1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201951-A1 | METHOD FOR PEPTIDE SYNTHESIS | Bachem Holding AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022204806-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | disclosed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022077121-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
| EP-3956348-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | Feldan Bio Inc. (CA) | 2022-02-23 | — | — | EP | disclosed |
| CN-114008210-A | Peptide-based non-protein cargo delivery | 费尔丹生物公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020210916-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2020-10-22 | — | — | WO | disclosed |
| CN-105189465-B | Synthesize the peptide prod containing hydantoins | 赛诺菲-安万特德国有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-10087221-B2 | Synthesis of hydantoin containing peptide products | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| EP-2976331-B1 | SYNTHESIS OF HYDANTOIN CONTAINING PEPTIDE PRODUCTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160289282-A1 | Synthesis of Hydantoin Containing Peptide Products | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2976331-A1 | SYNTHESIS OF HYDANTOIN CONTAINING PEPTIDE PRODUCTS | Sanofi-Aventis Deutschland GmbH (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105189465-A | Synthesis of hydantoin containing peptide products | SANOFI AVENTIS DEUTSCHLAND | 2015-12-23 | — | — | CN | disclosed |
| WO-2014147124-A1 | SYNTHESIS OF HYDANTOIN CONTAINING PEPTIDE PRODUCTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| US-4022910-A | L-3-hydroxymethyltyrosine and salts thereof for lowering blood pressure | RICHARDSON-MERRELL INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022910-A | L-3-hydroxymethyltyrosine and salts thereof for lowering blood pressure | RICHARDSON-MERRELL INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | SLC7A5 54/4885USP2 3024/4885KDM4E 1159/4885 |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | SLC7A5 35/4885USP2 2282/4885KDM4E 4852/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC7A5 860/4885USP2 319/4885KDM4E 2706/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | SLC7A5 3026/4885USP2 867/4885KDM4E 3959/4885 |
| US-20160289282-A1 | Synthesis of Hydantoin Containing Peptide Products | VIP, PEPD, HM13 | SLC7A5 1398/4885USP2 1966/4885KDM4E 1167/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | SLC7A5 2870/4885USP2 827/4885KDM4E 3957/4885 |
| US-10087221-B2 | Synthesis of hydantoin containing peptide products | VIP, PEPD, HM13 | SLC7A5 1398/4885USP2 1966/4885KDM4E 1167/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | SLC7A5 2566/4885USP2 633/4885KDM4E 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.